Zasocitinib, which is a potent and highly selective TYK2 inhibitor would be a good option for some of our patients who are ...

In this episode, the panel discusses the next wave of biologic development in atopic dermatitis, including bispecific ...

VTAMA was the only steroid-free topical AAD found supported by high certainty of evidence across all severities in children 2 years and older with AD.

Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.

The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD), will guide dermatologists in deciding the best possible prevention and treatment options for pediatric ...

CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology ...

This year’s American Academy of Dermatology Annual Meeting offered networking opportunities, late-breaking clinical research and hundreds of educational sessions, as well as forums supporting women’s ...

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and ...

Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American ...